The United Kingdom and the United States have signed a major commercial pact that will preserve zero tariffs on British medicine exports being sold in the US market.
The Terms of the Accord
Under the terms of the agreement, the UK has agreed to boost spending on drugs through the National Health Service (NHS). This pledge secures that import taxes on these crucial products will stay at nothing for a duration of three years.
This agreement follows recent statements to hike duties on patented drug products, with figures mentioned reaching double the cost.
"This agreement with the UK strengthens the international landscape for cutting-edge drugs and introduces much-needed balance to U.S.–U.K. pharmaceutical trade," an announcement noted.
Trade Impact
Drugs constitute one of the UK's most significant export categories to the America, which is by far the biggest market for major companies like GSK and AstraZeneca.
Statistics show that in the one-year period to the end of last September, the UK shipped medicines valued at £11.1bn to the US. This amount made up 17.4% of total UK exports in that timeframe.
"This deal secures jobs, stimulates investment and paves the way for the UK to emerge as a international leader for biotech and pharma," a government official commented.
Detailed UK Commitments
The deal includes several notable pledges from the UK:
- Price Threshold Increase: The UK will raise the price threshold at which it considers new treatments to be too expensive by 25%.
- Increased NHS Spending: There is a aim to increase overall health service expenditure on drugs from 0.3 percent of the national economy to 0.6 percent over the following ten-year period.
- Refund Ceiling: The amount drug companies must refund to the NHS to control costs will be limited at fifteen percent. Last year, refunds were more than twenty percent.
Recent Tensions
This agreement follows a ongoing tension between the sector and the British authorities over drug pricing and approval rates.
These tensions were heightened by claims that US customers were paying significantly more for the identical medicines than consumers in the Britain and the EU.
Recently, several significant drug company projects in the UK have been delayed or abandoned, while multi-billion-dollar investments have been pledged toward American operations.
One official acknowledged that the NHS must increase expenditure on treatments, noting that its spending on drugs had declined as a proportion of its resources over the previous ten-year period.
